---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-077416"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:41:10.086027+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share

## Summary
- Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.
- Net proceeds estimated at $141.1M, or $162.3M if over-allotment fully exercised.
- Underwriters include Goldman Sachs, Leerink Partners, Evercore, Barclays; closing expected Feb 27, 2026.
- Proceeds for general corporate purposes; shares sold under existing S-3ASR shelf registration.

## SEC filing metadata
- accession: 0001193125-26-077416
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/0001193125-26-077416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/d85338d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-077416
- JSON: https://secwatch.observer/filing/0001193125-26-077416.json
- Plain text: https://secwatch.observer/filing/0001193125-26-077416.txt

## Source-grounded claims
- claim_id: 03b05204755ac7842ad9cf3132d8143b96255307
  claim: Vir Biotechnology, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters valued at approximately $141.1 million (effective 2026-02-25).
  evidence_excerpt: On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/0001193125-26-077416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.